Results 21 to 30 of about 130,065,242 (295)

An In Vitro Model to Investigate the Potential of Solid Dispersions to Form Pharmacobezoars

Pharmaceutics, 2022
The formation of pharmacobezoars from suspensions of spray-dried amorphous solid dispersions (SD-ASDs) of new chemical entities (NCEs) and hydroxypropyl methylcellulose acetate succinate (HPMC-AS) represents a non-compound related adverse effect in ...
Hannes Gierke, Kerstin Schaefer, Lukas Gerlich, Ann-Cathrin Willmann, Verena Bialetzki, Georg Boeck, Teresa Pfrommer, Thomas Nolte, Werner Weitschies   +8 more
doaj   +1 more source

Ventilation‐induced epithelial injury drives biological onset of lung trauma in vitro and is mitigated with prophylactic anti‐inflammatory therapeutics

Bioengineering & Translational Medicine, 2022
Mortality rates among patients suffering from acute respiratory failure remain perplexingly high despite the maintenance of blood oxygen homeostasis during ventilatory support.
Eliram Nof, Arbel Artzy‐Schnirman, Saurabh Bhardwaj, Hadas Sabatan, Dan Waisman, Ori Hochwald, Maayan Gruber, Liron Borenstein‐Levin, Josué Sznitman   +8 more
doaj   +1 more source

OP0244 A PRECLINICAL TESTING TOOL: THE IN VITRO 3D FRACTURE GAP MODEL [PDF]

Annals of the Rheumatic Diseases, 2020
Background: Approximately 10% of fractures lead to significant fracture healing disorders, with a tendency to further increase due to the aging population. Of note, especially immunosuppressed patients with ongoing inflammation show difficulties in the correct course of fracture healing leading to fracture healing disorders.
M. Pfeiffenberger, A. Damerau, P. Hoff, A. Lang, F. Buttgereit, T. Gaber   +5 more
openaire   +1 more source

Cell Culture Based in vitro Test Systems for Anticancer Drug Screening

Frontiers in Bioengineering and Biotechnology, 2020
The development of new high-tech systems for screening anticancer drugs is one of the main problems of preclinical screening. Poor correlation between preclinical in vitro and in vivo data with clinical trials remains a major concern.
Kristina V. Kitaeva, Catrin S. Rutland, Albert A. Rizvanov, Albert A. Rizvanov, Valeriya V. Solovyeva   +4 more
doaj   +1 more source

An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer [PDF]

The Prostate, 2010
AbstractBACKGROUNDEven though patients with prostate cancer commonly respond to endocrine treatment, in most cases the disease progresses to castration resistant prostate cancer (CRPC). Our objective was to generate a novel cell line model representing the endocrine treatment naive prostate cancer for testing treatments that target the androgen ...
Pfeiffer, M.J., Mulders, P.F.A., Schalken, J.A.   +2 more
openaire   +3 more sources

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. [PDF]

PLoS ONE, 2018
Robust preclinical testing is essential to predict clinical safety and efficacy and provide data to determine safe dose for first-in-man studies. There are a growing number of examples where the preclinical development of drugs failed to adequately ...
Jane Harper, Katherine J Adams, Giovanna Bossi, Debbie E Wright, Andrea R Stacey, Nicole Bedke, Ruth Martinez-Hague, Dan Blat, Laure Humbert, Hazel Buchanan, Gabrielle S Le Provost, Zoe Donnellan, Ricardo J Carreira, Samantha J Paston, Luise U Weigand, Martina Canestraro, Joseph P Sanderson, Sophie Botta Gordon-Smith, Kate L Lowe, Karolina A Rygiel, Alex S Powlesland, Annelise Vuidepot, Namir J Hassan, Brian J Cameron, Bent K Jakobsen, Joseph Dukes   +25 more
doaj   +1 more source

National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing [PDF]

Pediatric Blood & Cancer, 2010
AbstractBackgroundThe National Cancer Institute (NCI) has established the Pediatric Preclinical Testing Program (PPTP) for testing drugs against in vitro and in vivo childhood cancer models to aid in the prioritization of drugs considered for early phase pediatric clinical trials.ProceduresIn vitro cytotoxicity testing employs a semi‐automated ...
Min H, Kang, Malcolm A, Smith, Christopher L, Morton, Nino, Keshelava, Peter J, Houghton, C Patrick, Reynolds   +5 more
openaire   +2 more sources

Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning [PDF]

Toxicologic Pathology, 1993
Myelosuppression is the dose-limiting side effect for most anti-cancer and many anti-human immunodeficiency virus agents, which can be quantitated with optimized colony-forming assays (granulocyte-macrophage, late erythroid, and megakaryocytic [for murine only] colony-forming units and early erythroid burst-forming units (BFUs)).
R E, Parchment, M, Huang, C L, Erickson-Miller   +2 more
openaire   +2 more sources

Implementation, availability and regulatory status of an OECD accepted Reconstructed Human Epidermis model in Brazil

Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia, 2018
Introduction: In 2014, Brazil has joined the growing list of countries to ban cosmetic products from being tested on animal models. The new legislation comes into force in 2019.
Rodrigo De Vecchi, Vanja Dakic, Guilherme Mattos, Anne-Sophie Rigaudeau, Veronica Oliveira, Cristina Garcia, Nathalie Alépée, José Cotovio, Charbel Bouez   +8 more
doaj   +7 more sources

Gas transport during in vitro and in vivo preclinical testing of inert gas therapies [PDF]

Medical Gas Research, 2016
New gas therapies using inert gases such as xenon and argon are being studied, which require in vitro and in vivo preclinical experiments. Examples of the kinetics of gas transport during such experiments are analyzed in this paper. Using analytical and numerical models, we analyze an in vitro experiment for gas transport to a 96 cell well plate and an
Katz, Ira, Palgen, Marc, Murdock, Jacqueline, Martin, Andrew R., Farjot, Géraldine, Caillibotte, Georges   +5 more
openaire   +2 more sources